Selective Inhibition of Regulatory T Cells by Targeting the PI3K–Akt Pathway

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer immunology research

• Publication date

  2014-07-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-14-0095PMID 25080445PMCID PMC4221428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

  2014cited by this paper
• Treg depletion followed by intracerebral CpG-ODN injection induce brain tumor rejection.

  2014cited by this paper
• Depletion of CD4+ CD25+ Regulatory T Cells Promotes CCL21-Mediated Antitumor Immunity

  2013cited by this paper
• Photodynamic therapy plus regulatory T-cell depletion produces immunity against a mouse tumour that expresses a self-antigen

  2013cited by this paper
• Signal Integration by Akt Regulates CD8 T Cell Effector and Memory Differentiation

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients

  2012cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Therapeutic cancer vaccines: are we there yet?

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval

  2011cited by this paper
• Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients

  2010cited by this paper
• Regulatory T Cell Suppression of Gag-Specific CD8+ T Cell Polyfunctional Response After Therapeutic Vaccination of HIV-1-Infected Patients on ART

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

  2010influential reference
• Phosphoinositide 3‐kinase and the mammalian target of rapamycin pathways control T cell migration

  2010influential reference
• Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

  2010cited by this paper
• T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

  2010cited by this paper
• WT1 peptide vaccination in a CML patient : induction of effective cytotoxic T lymphocytes and significance of peptide administration interval

  2010cited by this paper
• T cell activation.

  2009cited by this paper
• Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

  2009cited by this paper
• Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma.

  2008cited by this paper
• Incidence and Prognostic Impact of FoxP3+ Regulatory T Cells in Human Gliomas

  2008cited by this paper
• Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

  2008cited by this paper
• Combination of rapamycin and IL-2 increases de novo induction of human CD4(+)CD25(+)FOXP3(+) T cells.

  2008cited by this paper
• The Foxp3+ regulatory T cell: a jack of all trades, master of regulation

  2008cited by this paper
• Intracellular Signals of T Cell Costimulation

  2008cited by this paper
• Cutting Edge: Foxp3-Mediated Induction of Pim 2 Allows Human T Regulatory Cells to Preferentially Expand in Rapamycin1

  2008cited by this paper
• The AKT–mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells

  2008influential reference
• FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival

  2007cited by this paper
• Impaired T Cell Receptor Signaling in Foxp3+ CD4 T Cells

  2007cited by this paper
• Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.

  2007cited by this paper
• Flow cytometry-based methods for studying signaling in human CD4+CD25+FOXP3+ T regulatory cells.

  2007cited by this paper
• Selective Survival of Naturally Occurring Human CD4+CD25+Foxp3+ Regulatory T Cells Cultured with Rapamycin1

  2007cited by this paper
• Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.

  2006cited by this paper
• PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs.

  2006cited by this paper
• Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

  2005cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells.

  2005cited by this paper
• Development of effective immunotherapy for the treatment of patients with cancer.

  2004cited by this paper
• Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

  2004cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• The PI‐3 kinase/Akt pathway and T cell activation: pleiotropic pathways downstream of PIP3

  2003influential reference
• A push–pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L

  2002cited by this paper
• T‐cell antigen receptor signal transduction

  2002cited by this paper
• A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

  2002cited by this paper
• T cell antigen-receptor signal transduction.

  1999cited by this paper
• Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

  1996cited by this paper
• T-cell activation.

  1992cited by this paper
• Depletion of Treg cells inhibits minimal residual disease after surgery of HPV 16-associated tumours

  year unknowncited by this paper

• The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

  2026cites this paper
• Targeting PI3Kδ in cancer: a setback or the end

  2025cites this paper
• Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy

  2025cites this paper
• Dysregulated tryptophan metabolism: driving T cell subsets and PI3K-Akt pathway alterations in Hashimoto’s thyroiditis

  2025cites this paper
• Targeting hormone-related signals to reprogram the antitumor immune response in breast cancer: Research progress and application prospects.

  2025cites this paper
• PI3K/AKT signaling in parasites and parasite diseases: Role and therapeutic potential

  2025cites this paper
• Comprehensive analysis of PIK3CA mutations in advanced colorectal cancer using circulating tumor DNA profiling

  2025cites this paper
• CTLA-4—two pathways to anti-tumour immunity?

  2025cites this paper
• Nck1 regulates the in vitro development of human regulatory T cells through AKT pathway.

  2025cites this paper
• Regulatory T Cell Metabolism: A Promising Therapeutic Target for Cancer Treatment?

  2025cites this paper
• Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion

  2024cites this paper
• Metabolic targeting of regulatory T cells in oral squamous cell carcinoma: new horizons in immunotherapy

  2024cites this paper
• Cascade STING activation of a ternary immunostimulant for colorectal cancer eradication via photodynamic DNA damage and T regulatory cell inhibition

  2024cites this paper
• The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study

  2024cites this paper
• FAT10 induces immune suppression by upregulating PD-L1 expression in hepatocellular carcinoma

  2024cites this paper
• Targeting MEK/COX-2 axis improve immunotherapy efficacy in dMMR colorectal cancer with PIK3CA overexpression

  2024cites this paper
• Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

  2024cites this paper
• Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology

  2023cites this paper
• Targeting the oral tumor microenvironment by nanoparticles: A review of progresses

  2023cites this paper
• Small molecule inhibitors targeting regulatory T cells for cancer treatment

  2023cites this paper
• Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes

  2023cites this paper
• Zfp335 establishes eTreg lineage and neonatal immune tolerance by targeting Hadha-mediated fatty acid oxidation

  2023cites this paper
• Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation

  2023cites this paper
• Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment

  2023cites this paper
• Parkin Deficiency Suppresses Antigen Presentation to Promote Tumor Immune Evasion and Immunotherapy Resistance

  2023cites this paper
• Synergistic efficacy of PI3Kδ inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer

  2023cites this paper
• Immune Resistance Mechanisms and the Road to Personalized Immunotherapy.

  2023cites this paper
• Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials

  2023cites this paper
• Cutting the umbilical cord: Cancer stem cell-targeted therapeutics.

  2022cites this paper
• Distinct immunological and molecular signatures underpinning influenza vaccine responsiveness in the elderly

  2022cites this paper
• AKT Isoforms in the Immune Response in Cancer.

  2022cites this paper
• Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials

  2022cites this paper
• Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

  2022cites this paper
• Recent Advances and Challenges in Cancer Immunotherapy

  2022cites this paper
• Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

  2022cites this paper
• Clinical trials of immunotherapy in triple-negative breast cancer

  2022cites this paper
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

  2022cites this paper
• Immunosuppressive Signaling Pathways as Targeted Cancer Therapies

  2022cites this paper
• Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment

  2022cites this paper
• Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by intermittent anti-PI3Kα/β/δ treatment

  2022cites this paper
• The immunomodulatory effects of endocrine therapy in breast cancer

  2021influential citation
• Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives

  2021cites this paper
• The PI3K/Akt/mTOR pathway: A potential pharmacological target in COVID-19

  2021cites this paper
• A narrative review of combination therapy of PD-1/PD-L1 blockade with standard approaches for the treatment of breast cancer: clinical application and immune mechanism.

  2021cites this paper
• Up-regulated DNA-binding inhibitor Id3 promotes differentiation of regulatory T cell to influence antiviral immunity in chronic hepatitis B virus infection.

  2021cites this paper
• Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients

  2021cites this paper
• Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ

  2021influential citation
• Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

  2021cites this paper
• Immune checkpoint inhibitors in ovarian cancer: where do we stand?

  2021cites this paper
• PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism

  2021cites this paper
• PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity

  2021cites this paper
• The Importance of Being PI3K in the RAS Signaling Network

  2021cites this paper
• The therapeutic implications of immunosuppressive tumor aerobic glycolysis

  2021cites this paper
• Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.

  2021cites this paper
• PI3K inhibitors are finally coming of age

  2021cites this paper
• Treg: A Promising Immunotherapeutic Target in Oral Diseases

  2021cites this paper
• A Potential Role for Integrin-Linked Kinase in Colorectal Cancer Growth and Progression via Regulating Senescence and Immunity

  2021cites this paper
• Targeting Akt in Hepatocellular Carcinoma and Its Tumor Microenvironment

  2021cites this paper
• Immunomodulatory effects of PI3Kδ inhibition in solid tumors – evaluation in a randomized phase II trial

  2021cites this paper
• Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

  2021cites this paper
• The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies

  2020cites this paper
• Complementary approaches to study NKT cells in cancer.

  2020cites this paper
• Screening and Identifying Immune-Related Cells and Genes in the Tumor Microenvironment of Bladder Urothelial Carcinoma: Based on TCGA Database and Bioinformatics

  2020cites this paper
• ICOS-deficient and ICOS YF mutant mice fail to control Toxoplasma gondii infection of the brain

  2020cites this paper
• Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

  2020cites this paper
• Translational Landscape of mTOR Signaling in Integrating Cues Between Cancer and Tumor Microenvironment.

  2020cites this paper
• Tumor Microenvironment: Signaling Pathways – Part A

  2020influential citation
• Transient Inhibition of PI3Kδ Enhances the Therapeutic Effect of Intravenous Delivery of Oncolytic Vaccinia Virus

  2020cites this paper
• Intracellular mechanisms of tumor cells' immunoresistance.

  2020cites this paper
• Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey

  2020cites this paper
• Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

  2020cites this paper
• Correlation of the levels of DNA-binding inhibitor Id3 and regulatory T cells with SLE disease severity.

  2020cites this paper
• Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

  2020cites this paper
• Targeting Disseminated Estrogen-Receptor-Positive Breast Cancer Cells in Bone Marrow

  2020cites this paper
• FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets.

  2020cites this paper
• Effect and biomarker of immune checkpoint blockade therapy for ARID1A deficiency cancers.

  2020cites this paper
• The Immunotoxicity of Chronic Exposure to High Levels of Lead: An Ex Vivo Investigation

  2020cites this paper
• PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

  2020cites this paper
• Emerging roles of class I PI3K inhibitors in modulating tumor microenvironment and immunity

  2020cites this paper
• Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

  2020cites this paper
• Overcoming resistance to immune checkpoint therapy in PTEN-null prostate cancer by sequential intermittent anti-PI3Kα/β/δ and anti-PD-1 treatment

  2020influential citation
• Transcriptional Control of Regulatory T Cells in Cancer: Toward Therapeutic Targeting?

  2020cites this paper
• Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer

  2020cites this paper
• Weichang’an Formula Inhibits Tumor Growth in Combination with Bevacizumab in a Murine Model of Colon Cancer—Making up for the Deficiency of Bevacizumab by inhibiting VEGFR-1

  2020cites this paper
• Immunometabolism of regulatory T cells in cancer.

  2020cites this paper
• Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals.

  2020cites this paper
• Immunomodulation by targeted anticancer agents.

  2020cites this paper
• Signaling Dynamics Regulating Crosstalks between T-Cell Activation and Immune Checkpoints.

  2020cites this paper
• Screening of tumor microenvironment-related prognostic genes in breast cancer by data mining

  2020cites this paper
• Risk variants disrupting enhancers of TH1 and TREG cells in type 1 diabetes

  2019cites this paper
• The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function

  2019cites this paper
• Targeting Tumor Microenvironment by Small-Molecule Inhibitors

  2019cites this paper
• The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas.

  2019cites this paper
• On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors

  2019cites this paper
• Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer

  2019cites this paper
• Metabolic Control of Treg Cell Stability, Plasticity, and Tissue-Specific Heterogeneity

  2019cites this paper
• PI3K isoforms in cell signalling and vesicle trafficking

  2019cites this paper
• Treg-mediated acquired resistance to immune checkpoint inhibitors.

  2019cites this paper
• FOXP3 and Its Cofactors as Targets of Immunotherapies

  2019cites this paper
• PI 3 ‐ kinase isoforms at the crossroads of signalling and vesicular traffic

  2019cites this paper